Breakthrough Therapeutics for Intractable Diseases

Neurodon is taking a different approach by targeting stress pathways common to the most devastating diseases.

We are a development-stage pharmaceutical company that is developing disease-modifying molecules targeting neurodegeneration, diabetes, and other life-threatening conditions by deploying a proprietary ER stress-based technology platform — halting diseases and improving lives with innovative small molecule therapies.

Innovative Science

Our focus is two-fold: rigorous scientific investigation coupled with expedient clinical translation.

Neurodon’s deep understanding of pathological cellular pathways and decades of experience in drug development and clinical translation have enabled the development of medicines that show promise to treat some of the most challenging diseases of our time.

OUR SCIENCE
  • Press Release
    READ THIS ARTICLE
  • Press Release
    READ THIS ARTICLE
Curing the Incurable logo

Partners and Investors

Neurodon actively collaborates with institutions on pioneering advancements to validate new therapeutic candidates with novel targets.

Loyola University Chicago logo
Northwestern logo
Harvard Medical School logo
NIH National Insitute of Health logo
Elevate Ventures logo
UT Southwestern Medical Center logo

A First-in-Class Pipeline

Progressing a portfolio of small molecules.

VIEW PIPELINE
VIEW PIPELINE